Affibody and Agilent to Develop Protein Sample
News Sep 07, 2005
Affibody AB and Agilent Technologies Inc. have announced a cooperative agreement to develop advanced protein sample preparation solutions for human biomarker discovery.
Affibody will design and develop engineered Affibody® ligands for specific protein targets designated by Agilent, which Agilent plans to use to expand its line of proteomic sample preparation products. At the end of the development phase of the agreement, Affibody will supply Agilent with production quantities of the materials.
Under the agreement, Affibody will deliver highly specific and robust affinity capture ligands that will enable Agilent to expand its market-leading Multiple Affinity Removal System technology with new product configurations.
According to Agilent, these products will enable scientists involved in biomarker discovery from human serum/plasma to continue to dig deeper into the serum proteome, in order to discover and identify potential biomarkers that can be used for human disease diagnosis, monitoring of therapeutic intervention, and prognosis.
Agilent claims that, the robustness of the Affibody® ligand permits unsurpassed reproducibility for sample-to-sample comparison, resulting in greater certainty and clarity of scientific data.
"By using the versatile Affibody® ligands, we´ll be offering our customers a tool to further refine the precision, certainty and reproducibility of proteomics analyses," said Mary Pat Knauss, business manager of Agilent´s Bioreagents Products.
She adds, "The combination of this technology with our current protein fractionation and separation products will enable researchers to dive deeper into the serum/plasma proteome than ever before possible, enhancing their efforts to identify biological markers."
"Agilent is a leading player in the proteomics arena, and we are delighted that they choose Affibody® ligands for use in their products," said Torben Jørgensen, CEO of Affibody.
He adds, "This agreement is yet another confirmation of the great commercial interest for Affibody® molecules, and the collaboration with Agilent goes well in hand with our firm commitment to establish a long term market presence."
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE